(Q36799846)

16 August 2017

1 reference

title

Xenograft models for the preclinical evaluation of new therapies in acute leukemia (English)

1 reference

16 August 2017

1 reference

1 reference

Erwin M Lee

1

1 reference

16 August 2017

Petra S Bachmann

series ordinal

2

1 reference

16 August 2017

Richard B Lock

series ordinal

3

1 reference

16 August 2017

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

48

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

659-668

1 reference

Childhood acute lymphoblastic leukemia

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Modeling metastasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Hereditary asplenic-athymic mice: transplantation of human myelogenous leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

A severe combined immunodeficiency mutation in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

A model of human acute lymphoblastic leukemia in immune-deficient SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The SCID mouse mutant: definition, characterization, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

SCID mouse models of human stem cell engraftment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/beta2-microglobulin(null) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Animal models of acute myelogenous leukaemia - development, application and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Direct and serial transplantation of human acute myeloid leukaemia into nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

FLT-3: a new focus in the understanding of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Characterization of a Zinc Finger Gene Disrupted by the t(15;17) in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Retinoic acid syndrome in NOD/scid mice induced by injecting an acute promyelocytic leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Orthotopic models are necessary to predict therapy of transplantable tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Spontaneous and genetically engineered animal models; use in preclinical cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

TGN1412: scrutinizing preclinical trials of antibody-based medicines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

The strange case of TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601113584

10.1080/10428190601113584

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference